MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride
10/7/2013 9:46:10 AM
SAN DIEGO, Oct. 6, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-029 (denibulin) di-hydrochloride.
Help employers find you! Check out all the jobs and post your resume.
comments powered by